For Patients

Hepatitis B and C Treatments

A complete list of currently approved FDA therapies to treat Hepatitis B and C.

Click on drug brand name for additional information.

Approved Treatments for Hepatitis B

Brand Name Generic
Names
Manufacturer Name Indication
Baraclude entecavir Bristol-Myers Squibb chronic hepatitis B virus infection with evidence of active viral replication
Epivir HBV lamivudine GlaxoSmithKline chronic hepatitis B associated with
hepatitis B viral replication and active liver inflammation
Hepsera adefovir dipivoxil Gilead Sciences chronic hepatitis B in patients ≥12 years of age
Intron A interferon alpha-2b Schering chronic hepatitis B in patients 1 year of age or older with compensated liver disease
Pegasys pegylated interferon Roche treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation
Tyzeka telbivudine Novartis chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Viread tenofovir Gilead Sciences chronic hepatitis B in adults.
 

Approved Treatments for Hepatitis C

Brand Name Generic Names Manufacturer Name Indication
CoPegus ribavirin Roche use in combination with Pegasys or with Roferon for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha
Daklinza daclatasvir Bristol-Myers Squibb Company an NS5A replication complex inhibitor is indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving this regimen. The recommended dosage of DAKLINZA is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DAKLINZA may be taken with or without food.The optimal duration of DAKLINZA and sofosbuvir for patients with cirrhosis has not been established.
Epclusa sofosbuvir, velpatasvir Gilead a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection -without cirrhosis or with compensated cirrhosis or with decompensated cirrhosis for use in combination with ribavirin
Harvoni ledipasvir/sofosbuvir Gilead a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Incivek telaprevir Vertex Pharmaceuticals in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers
Infergen interferon aphacon-1 Three Rivers Pharma treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and/or HCV RNA
Intron A interferon alpha-2b Schering treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive
Olysio simeprevir Janssen Pharmaceuticals for the treatment of chronic hepatitis C (CHC) genotype 1 infection as a component of a combination antiviral treatment regimen
Pegasys pegylated interferon Roche treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha
Pegintron pegylated interferon alpha-2b Schering

in combination with rebetol, is indicated for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease use alone for the treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age and intolerant to ribavirin

Rebetol ribavirin Schering use in combination with Pegintron for treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and are at least 18 years of age
Roferon interferon alpha-2a Roche treatment of chronic hepatitis C in patients 18 years of age or older
Sovaldi sofosbuvir Gilead Sciences for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen
Technivie ombitasvir, paritaprevir and ritonavir AbbVie Inc. a fixed-dose combination containing ombitasvir, a hepatitis C virus NS5A inhibitor; paritaprevir, a hepatitis C virus NS3/4A protease inhibitor; and ritonavir, a CYP3A inhibitor. The product is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis.
Victrelis boceprevir Merck & Co. treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years of age and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.
Viekira Pak ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets AbbVie Inc. use with or without ribavirin for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis
Zepatier elbasvir, grazoprevir Merck Sharp Dohme a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated with or without ribavirin for treatment of chronic HCV genotypes 1 or 4 infection in adults

 

Page Last Updated: 08/09/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English